UK parliament discusses adding MLD screening to newborn heel prick tests

A Member of Parliament urged health ministers to include Metachromatic Leukodystrophy (MLD) screening in the United Kingdom's newborn heel prick test.

MLD is a genetic disease that progressively destroys the nervous system, often causing children to lose their ability to walk, speak, and breathe before they reach age five. The National Institute for Health and Care Excellence (NICE) approved a gene therapy for MLD in 2022, which is now available through the National Health Service (NHS).

This treatment can halt the disease and has shown 100% survival rates in late-infantile patients, provided the condition is detected early enough to prevent permanent damage. Experts at the Royal Manchester Children’s Hospital provide this treatment, but it requires a diagnosis before symptoms appear. Adding MLD to the existing screening for 10 conditions would cost 17 pence per baby and less than £100,000 per year.

The Member of Parliament noted that other countries, including Norway, Sweden, Canada, Italy, and the USA, have already implemented MLD screening. The leader of the House of Commons acknowledged that early diagnosis is essential and agreed to facilitate a meeting between the Member of Parliament and health ministers to discuss the change.